| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| S2015- | E | SWOG | 6 | |||
| sum | 6 | |||||
| BREAST | S1706-Breast, Inflammatory, RT +/- Olaparib | Y | ALLIANCE | 10 | ||
| CCTG | 6 | |||||
| ECOG-ACRIN | 5 | |||||
| NRG | 34 | |||||
| SWOG | 49 | |||||
| sum | 104 | |||||
| S2007-Breast, Brain Mets, Sacituzumab Govitecan | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 1 | |||||
| SWOG | 6 | |||||
| sum | 11 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 4 | ||
| ECOG-ACRIN | 16 | |||||
| NRG | 14 | |||||
| SWOG | 194 | |||||
| sum | 228 | |||||
| S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 1 | |||||
| SWOG | 25 | |||||
| sum | 30 | |||||
| ERLYTX | S1609-Rare Tumor, Comb Nivo/Ipi | Y | ALLIANCE | 105 | ||
| ECOG-ACRIN | 78 | |||||
| NRG | 137 | |||||
| SWOG | 473 | |||||
| sum | 793 | |||||
| S2012-Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 1 | |||
| sum | 1 | |||||
| GI | S1613-mCRC, Adv/Met, TP vs CETIRI | 31-MAR-22 | N | ALLIANCE | 6 | |
| ECOG-ACRIN | 4 | |||||
| NRG | 5 | |||||
| SWOG | 39 | |||||
| sum | 54 | |||||
| S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 2 | |||||
| SWOG | 11 | |||||
| sum | 21 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 1 | |||||
| SWOG | 10 | |||||
| sum | 15 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | NRG | 2 | |||
| SWOG | 2 | |||||
| sum | 4 | |||||
| GU | S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | Y | ALLIANCE | 81 | ||
| ECOG-ACRIN | 56 | |||||
| NRG | 66 | |||||
| SWOG | 362 | |||||
| sum | 565 | |||||
| S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 27 | |||||
| NRG | 86 | |||||
| SWOG | 163 | |||||
| sum | 294 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 1 | |||||
| SWOG | 29 | |||||
| sum | 33 | |||||
| S1937-Blad, Mets, Eribulin +/- Gem vs SOC | Y | NRG | 1 | |||
| SWOG | 9 | |||||
| sum | 10 | |||||
| LEUK | S1712-CML, Chronic Phase, TKI +/- Ruxolitinib | Y | ALLIANCE | 11 | ||
| ECOG-ACRIN | 6 | |||||
| NRG | 2 | |||||
| SWOG | 57 | |||||
| sum | 76 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | ALLIANCE | 2 | |||
| SWOG | 8 | |||||
| sum | 10 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 4 | |||||
| SWOG | 19 | |||||
| sum | 27 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 622 | ||
| ECOG-ACRIN | 298 | |||||
| NRG | 316 | |||||
| SWOG | 1331 | |||||
| sum | 2567 | |||||
| S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 2 | |||||
| SWOG | 13 | |||||
| sum | 18 | |||||
| S1800D-Non-Match: N-803 + Pembro vs SoC | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 1 | |||||
| SWOG | 18 | |||||
| sum | 25 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 11 | |||
| CCTG | 11 | |||||
| ECOG-ACRIN | 2 | |||||
| NRG | 42 | |||||
| SWOG | 36 | |||||
| sum | 102 | |||||
| S1900E-KRAS G12C: Sotorasib (AMG 510) | Y | ALLIANCE | 13 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 4 | |||||
| SWOG | 38 | |||||
| sum | 66 | |||||
| S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 13 | |||||
| SWOG | 81 | |||||
| sum | 108 | |||||
| S1929-ESCLC, SLFN11+, Atezolizumab ± Talazoparib | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 7 | |||||
| NRG | 5 | |||||
| SWOG | 64 | |||||
| sum | 83 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 2 | |||
| NRG | 1 | |||||
| SWOG | 20 | |||||
| sum | 23 | |||||
| LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | T | ALLIANCE | 15 | ||
| ECOG-ACRIN | 5 | |||||
| NRG | 11 | |||||
| SWOG | 41 | |||||
| sum | 72 | |||||
| S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | Y | ALLIANCE | 119 | |||
| CCTG | 21 | |||||
| COG | 288 | |||||
| ECOG-ACRIN | 77 | |||||
| NRG | 44 | |||||
| SWOG | 345 | |||||
| sum | 894 | |||||
| S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 2 | |||||
| SWOG | 10 | |||||
| sum | 35 | |||||
| MELAN | S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 05-MAY-22 | N | ALLIANCE | 32 | |
| ECOG-ACRIN | 50 | |||||
| NRG | 47 | |||||
| SWOG | 216 | |||||
| sum | 345 | |||||
| S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 1 | |||||
| SWOG | 7 | |||||
| sum | 12 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 139 | ||
| ECOG-ACRIN | 117 | |||||
| NRG | 72 | |||||
| SWOG | 473 | |||||
| sum | 801 | |||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ECOG-ACRIN | 1 | |||
| sum | 1 | |||||
| PEOLC | S1820-Rectal, Diet modification to manage GI sx | 27-APR-22 | N | ALLIANCE | 4 | |
| ECOG-ACRIN | 1 | |||||
| NRG | 29 | |||||
| SWOG | 61 | |||||
| sum | 95 | |||||
| PREV | S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | Y | ALLIANCE | 36 | ||
| ECOG-ACRIN | 30 | |||||
| NRG | 38 | |||||
| SWOG | 235 | |||||
| sum | 339 | |||||
| S1823-GCT, Obs. Cohort, miRNA371 | Y | ALLIANCE | 61 | |||
| CCTG | 90 | |||||
| ECOG-ACRIN | 39 | |||||
| NRG | 25 | |||||
| SWOG | 313 | |||||
| sum | 528 | |||||
| S1904-Breast, Decision making for chemoprevention | Y | ALLIANCE | 44 | |||
| ECOG-ACRIN | 21 | |||||
| NRG | 37 | |||||
| SWOG | 81 | |||||
| sum | 183 | |||||
| SURV | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 34 | ||
| SWOG | 199 | |||||
| S1501 | Y | ALLIANCE | 20 | |||
| NRG | 20 | |||||
| sum | 273 | |||||
| SXQOL | S1600-Bladder,Radical Cystectomy Outcomes Nutrition | Y | ALLIANCE | 5 | ||
| NRG | 1 | |||||
| SWOG | 134 | |||||
| sum | 140 | |||||
| S1614-HBV in Ca Pts, anti-HBV therapy vs SOC | Y | NRG | 1 | |||
| SWOG | 3 | |||||
| sum | 4 | |||||
| S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 39 | |||
| ECOG-ACRIN | 24 | |||||
| NRG | 28 | |||||
| SWOG | 218 | |||||
| sum | 309 | |||||